UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero

Goulden, Bethan; Chua, Nicole; Parker, Elaine; Giles, Ian; (2022) A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology , 61 (10) pp. 3902-3906. 10.1093/rheumatology/keac141. Green open access

[thumbnail of Giles_A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero_AAM.pdf]
Preview
Text
Giles_A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero_AAM.pdf

Download (216kB) | Preview

Abstract

OBJECTIVES: Transplacental passage of certain biologic- and targeted synthetic DMARDs leads to detectable levels in the neonate, which may impact on the safety of live vaccines. Guidelines advise delaying live vaccine administration in biologic exposed infants until they are 7 months old. METHODS: A systematic review of Embase, Medline and Cochrane identified live vaccine outcomes in infants exposed to biologic or targeted synthetic DMARDs in-utero. RESULTS: Studies included 276 in-utero exposures to adalimumab, certolizumab, etanercept, infliximab, golimumab, tocilizumab and ustekinumab. Live vaccine exposures <12 months of age included BCG (n = 215), rotavirus (n = 46) and MMR (n = 12). We identified no reactions following MMR, 7 mild reactions to rotavirus vaccination, and 8 reactions to BCG including one death. All infants with an adverse reaction to BCG had been exposed to infliximab in-utero, and 6 had received BCG in the first month of life. A freedom of information request to the Medicines and Healthcare products Regulatory Agency revealed 4 fatal disseminated BCG infections in infants exposed to TNF inhibitors in-utero, including infliximab, adalimumab and one unspecified TNF inhibitor. CONCLUSION: Most evidence for clinically harmful effect was for early administration of the BCG vaccine to infants exposed in-utero to TNF inhibitors with high transplacental transfer rates.

Type: Article
Title: A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/rheumatology/keac141
Publisher version: https://doi.org/10.1093/rheumatology/keac141
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: pregnancy and rheumatic disease, biological therapies, RA, DMARDs, immunosuppressants
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10147909
Downloads since deposit
138Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item